Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1CNS 1

Conditions

Neoplasms 1Ganglioneuroblastoma 1

Interventions

pembrolizumab 20Cisplatin 14Carboplatin 13Paclitaxel 12Radiation 11Doxorubicin 10Radiotherapy 9Nivolumab 9Cyclophosphamide 9Cytarabine 8Vincristine 7Radiotherapy, Intensity-Modulated 7Metformin 7Magnetic Resonance Spectroscopy 7Etoposide 7Leucovorin 6Ipilimumab 6Injections 6Fluorouracil 6Docetaxel 6tislelizumab 5Specimen Handling 5Radiotherapy, Conformal 5Prednisone 5Pemetrexed 5Methotrexate 5Cetuximab 5Bevacizumab 5fludarabine 4durvalumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Isotretinoin × 30 days × Clear all
NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT03611595 2026-05-27

Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid Tumors

University of California, San Diego

Phase 1 Completed
15 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡